Investment
Features
FeesSafety
Academy
More
Pluang+

Compare US Global Jets ETF (JETS) vs Novartis AG (NVS) Price & Performance

US Global Jets ETFTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

US Global Jets ETF vs Novartis AG — how do they compare? US Global Jets ETF trades at $30.55, while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals.

JETSNVS
Sector
Sector/ThematicHealth
52-Week High
$33.34$168.62
52-Week Low
$23.12$113.50
Market Cap
$290.25B
Enterprise Value
$330.27B
Dividend Yield
3.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

US Global Jets ETF

JETS trades at $30.58, up 0.39% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF faces headwinds from rising fuel costs as U.S. airlines spent $6.66 billion on jet fuel in May 2026 (U.S. Transportation Department, July 2026), though falling oil prices recently provided some relief. Technical indicators show RSI levels in oversold territory at 24.66 for the 12-day period, suggesting potential buying opportunity.

The outlook remains cautious as airline profits face pressure from fuel volatility and Middle East conflict impacts. While lower oil prices offer temporary relief, the sector's cyclical nature and competitive dynamics with defense-focused ETFs present ongoing challenges. Investment opportunity exists for those betting on travel recovery, but risks from fuel price shocks and operational disruptions require careful monitoring.

Novartis AG

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About US Global Jets ETF

JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.

Read more on JETS

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS